This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


FDA adds Fasenra indication for severe asthma in children

FDA adds fasenra indication for severe asthma in children

The U.S. Food and Drug Administration has approved an additional indication for AstraZeneca's Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic phenotype.

This indication was supported by evidence from the Phase III TATE trial, as well as from additional well-controlled trials in adult and adolescent populations. Results among aged 6 to 11 years old show that Fasenra met the primary end points, demonstrating pharmacokinetics and pharmacodynamics with severe eosinophilic asthma. The and tolerability results were also consistent with the known profile.

The recommended dose for Fasenra is 30 mg for patients ages 6 years and older who weigh ≥35 kg, while a new 10-mg dose will be available for patients aged 6 to 11 years who weigh <35 kg. Fasenra is administered by subcutaneous injection every four weeks for the first three doses and then every eight weeks.

"We welcome additional treatment options for children living with severe asthma, a condition that remains complicated to manage, further helping to address the unmet need in this patient population and reducing the burden of disease for the broader asthma community," Lynda Mitchell, of the Allergy & Asthma Network, said in a statement.

More information: More Information

Copyright © 2024 HealthDay. All rights reserved.

Citation: FDA adds Fasenra indication for severe asthma in children (2024, April 17) retrieved 26 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Tapering of inhaled steroids feasible for asthma controlled with benralizumab


Feedback to editors